A phase I single dose study for the intravenous (IV) formulation of TPOXX (tecovirimat) for the treatment of orthopoxvirus disease

Trial Profile

A phase I single dose study for the intravenous (IV) formulation of TPOXX (tecovirimat) for the treatment of orthopoxvirus disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Tecovirimat (Primary)
  • Indications Orthopoxvirus infections; Smallpox
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 20 Apr 2017 According to a SIGA Technologies media release, the company has completed enrollment and dosing in the final cohort of this trial.
    • 20 Apr 2017 Results published in a SIGA Technologies media release.
    • 20 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to a SIGA Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top